News Jun 20, 2014 Stemedica plans to initiate Phase IIa 70-patient Alzheimer’s disease trial this year – executive Another Stemedica subsidiary, CardioCell, has an exclusive, worldwide license for IV-administered allogeneic ischemia-tolerant mesenchymal stem cells (itMSCs).
Read MoreCardioCell Scientific Advisory Board Member Presents at the 2014 Lugano Stem Cell Meeting
News Jun 16, 2014 CardioCell Scientific Advisory Board Member Presents at the 2014 Lugano Stem Cell Meeting LUGANO, SWITZERLAND – LUGANO STEM CELL MEETING – June 16, 2014 – CardioCell LLC, a Stemedica Cell Technologies subsidiary that creates allogeneic stem-cell therapies for
Read MoreIndonesia’s BPOM Grants IND Approval for SCI to Conduct a Phase II Clinical Trial Using Stemedica’s Mesenchymal Stem Cells to Treat Acute Myocardial Infarction
News May 27, 2014 Indonesia’s BPOM Grants IND Approval for SCI to Conduct a Phase II Clinical Trial Using Stemedica’s Mesenchymal Stem Cells to Treat Acute Myocardial Infarction SAN DIEGO — May 27, 2014 — Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic
Read MoreCardioCell Scientific Advisory Board Members Present at the 2014 World Congress on Acute Heart Failure
News May 14, 2014 CardioCell Scientific Advisory Board Members Present at the 2014 World Congress on Acute Heart Failure ATHENS, GREECE – WORLD CONGRESS ON ACUTE HEART FAILURE– May 14, 2014 – CardioCell announces presentations by prominent chronic heart failure (CHF) opinion leaders
Read MoreCardioCell Scientific Advisory Board Chair Joins “Novel Technologies in Stem Cell Research” Panel at the 2014 Stem Cell Summit
News Apr 21, 2014 CardioCell Scientific Advisory Board Chair Joins “Novel Technologies in Stem Cell Research” Panel at the 2014 Stem Cell Summit CAMBRIDGE, MASS. – STEM CELL SUMMIT 2014 – April 21, 2014 – CardioCell announces a presentation by noted cardiologist Dr. Stephen Epstein,
Read MoreStem cell trial is approved for patients with heart failure
News Apr 5, 2014 Stem cell trial is approved for patients with heart failure CardioCell has received approval from the FDA for a Phase IIa clinical trial of its allogeneic stem cell therapy for chronic heart failure. READ FULL ARTICLE
Read MoreFDA Approves CardioCell’s Phase 2A Trial For CHF Stem Cell Therapy
News Apr 4, 2014 FDA Approves CardioCell's Phase 2A Trial For CHF Stem Cell Therapy CardioCell LLC announced that it has received FDA approval for its investigational new drug (IND) application for a U.S.-based Phase IIA clinical study evaluating its allogeneic stem-cell therapy for
Read MoreCardioCell to scout for CROs for PAD trial with allogeneic mesenchymal stem cells, in partnership talks – CEO
News Apr 4, 2014 CardioCell to scout for CROs for PAD trial with allogeneic mesenchymal stem cells, in partnership talks –
Read More